Avert-IT

Intensive Care patients can experience Adverse Events associated with sudden episodes of low blood pressure. These Adverse Events may impact all of the main organs resulting in longer lengths of stay, increased care costs and reducing quality of outcomes. Existing technologies enable to clinicians to know when these events have occurred and treat the effects.

Medical techniques for avoiding Adverse Events currently exist, but clinicians don#t have a reliable way to predict the occurrence, so there is no opportunity for intervention.

Research indicates average lengths of stay can be reduced by up to 30%, and outcomes improved for a similar proportion of patients, if these Adverse Events can be avoided through prediction and intervention. Potential savings across the EU exceed 5 billion euros, annually.

A model for predicting Adverse Events offers potential for improving outcomes across a wide range of conditions and or illnesses.

The main objectives of the project are:

  • Understanding the association between multiple patient parameters and arterial hypotension (sudden drop in blood pressure)
  • Development of a software application to predict the occurrence of arterial hypotension based on recognition of the associations described above
  • Validation of the solution in clinical trials
  • Exploitation model for the commercialisation of the software in product/service sales across international markets

For further information, please visit:
http://avertit.wordpress.com (Avert-IT Project Blog)

Project co-ordinator:
Pera Innovation Ltd.

Partners:

  • C3 Amulet Ltd
  • Uppsala Universitet
  • Universitätsklinikum Heidelberg
  • Azienda Ospedaleria San Gerardo Di Monza
  • Kauno Technologijos Universitetas
  • The University Of Glasgow
  • Greater Glasgow Health Board
  • Hospital Universitari Vall d'Hebron
  • Philips Medizin Systeme Böblingen Gmbh.

Timetable: from 01/2008 € to 12/2010

Total cost: € 2.286.138

EC funding: € 1.780.000

Programme Acronym: FP7-ICT

Subprogramme Area: Advanced ICT for risk assessment and patient safety

Contract type: Collaborative project (generic)


Related news article:

Most Popular Now

Artificial Intelligence Solution Improve…

Clinical trials are a critical tool for getting new treatments to people who need them, but research shows that difficulty finding the right volunteer subjects can undermine the effectiveness of...

Cardio-Respiratory Synchronization may R…

Researchers from the School of Engineering at the University of Warwick have managed to expand the knowledge of the cardio-respiratory system after conducting an experiment measuring heart rate during fast-paced...

South West London Pathology Picks CliniS…

One of the first pathology networks in the country, set up to serve more than two million people in south west London, has signed a contract with CliniSys for a...

AI-based AI-Rad Companion Chest CT Softw…

AI-Rad Companion Chest CT(1), an intelligent software assistant for radiology, was recently awarded the CE mark, which means Siemens Healthineers can start marketing this artificial intelligence (AI)-based software as a...

Spot On for Healthcare Technology Startu…

10 - 12 October 2019, Berlin, Germany. XPOMET Medicinale brings together care providers, patients, and in general stakeholders from all health-related fields and geographic regions. The Festival of Future Medicine and...

Call for Tenders: Studies on eHealth, In…

The European Commission is launching a tender for two studies to survey and analyse progress on the digital transformation of the health and care in the EU, in particular with...

7th MEDICA MEDICINE + SPORTS CONFERENCE

18 - 21 November 2019, Düsseldorf, Germany. What lengths do top athletes go to in order to reach peak performances and which findings in the field of professional sports are relevant...

Carestream Health Completes Sale of Heal…

Carestream Healthhas completed the sale of the company's healthcare information solutions business to Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, in 26 of the 38...

How can We Successfully Converge the Hea…

Opinion Article by Erik Janssen, VP, Innovative Solutions, Neurology, UCB Pharma. The fourth industrial revolution is upon us and fundamentally changing the way we live, work and interact across all industries...

Isansys Named as Finalist for OBN's Most…

Isansys Lifecare is proud to announce it has been shortlisted in the Most Transformative Digital Healthcare Company category at the OBN Annual Awards 2019. The award recognises the significant uptake...